Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma

• Published in: The Journal of experimental medicine Vol. 179; no. 5; pp. 1409 - 1415
• Main Authors: SMITH, D. R, POLVERINI, P. J, KUNKEL, S. L, ORRINGER, M. B, WHYTE, R. I, BURDICK, M. D, WILKE, C. A, STRIETER, R. M
• Format: Journal Article
• Language: English
• Published: New York, NY Rockefeller University Press 01.05.1994; The Rockefeller University Press
• Subjects: Animals; Biological and medical sciences; Carcinoma, Bronchogenic - blood supply; Chemotaxis; Endothelium, Vascular - cytology; Female; Humans; Immunohistochemistry; Interleukin-8 - antagonists & inhibitors; Interleukin-8 - physiology; Lung - chemistry; Lung Neoplasms - blood supply; Medical sciences; Neovascularization, Pathologic - etiology; Pneumology; Rats; Rats, Inbred F344; Tumors of the respiratory system and mediastinum; Human; Angiogenesis; Carcinoma; Respiratory disease; Pathogenesis; Cytokine; Bronchus disease; Malignant tumor; Chemotaxis; Biological activity; Bronchopulmonary; Interleukin 8
• ISSN: 0022-1007; 1540-9538
• DOI: 10.1084/jem.179.5.1409

We investigated the role of interleukin 8 (IL-8) in mediating angiogenesis in human bronchogenic carcinoma. Increased quantities of IL-8 were detected in tumor tissue as compared with normal lung tissue. Immunohistochemical staining of tumors revealed primary localization of IL-8 to individual tumor cells and demonstrated the capacity of tumor to elaborate IL-8. Functional studies that used tissue homogenates of tumors demonstrated the induction of both in vitro endothelial cell chemotaxis and in vivo corneal neovascularization. It is important to note that the addition of neutralizing antisera to IL-8 to these assays resulted in the marked and specific attenuation of these responses. Our observations definitively establish IL-8 as a primary mediator of angiogenesis in bronchogenic carcinoma and offer a potential target for immunotherapies against solid malignancies.